Literature DB >> 25714237

Consistent ovulation may not be enough to make women healthy when approaching menopause: an update from the Study of Women's Health Across the Nation.

Amanda A Allshouse1, Alex Polotsky, Sybil Crawford, Hsiang-Yu Chen, Samar R El Khoudary, Nanette Santoro.   

Abstract

OBJECTIVE: This study aims to test the hypothesis that consistently ovulatory premenopausal/perimenopausal women have a more favorable cardiometabolic profile than anovulatory women.
METHODS: The first four collections from the Study of Women's Health Across the Nation Daily Hormone Study (DHS) were used. DHS enrollees annually completed a daily collection of first morning voided urine for an entire menstrual cycle or up to 50 days (whichever comes first). A woman was categorized as consistently ovulatory annually (COA) if four ovulatory cycles or two to three ovulatory cycles followed by the final menstrual period (FMP) were observed. A woman was categorized as not consistently ovulatory annually (nCOA) if at least one anovulatory year was observed. Cross-sectional and longitudinal differences were compared between COA and nCOA women. Data were centered at FMP and adjusted for age and body mass index (BMI).
RESULTS: Six hundred thirty-six DHS participants (mean [SD] age, 47.3 [2.5] y; mean [SD] BMI, 27.4 [7.1] kg/m(2)) were included. Thirty-six percent of the DHS participants were COA women. On the fourth follow-up collection, COA women had lower high-density lipoprotein than nCOA women (mean [95% CI], 55.7 [54.0-57.4] vs 59.5 [57.9-61.0] mg/dL, P = 0.002, respectively), which persisted after adjustment. Among 460 women with FMP, 39% were COA women. COA women were slightly older (52.9 vs 52.0 y, P = 0.002) and had lower BMI (geometric mean, 26.1 vs 27.5 kg/m(2), P = 0.06) than nCOA women at FMP. Other cardiometabolic factors did not significantly differ by COA status through FMP.
CONCLUSIONS: Consistent ovulation across the menopausal transition does not seem to reflect superior cardiometabolic health.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25714237      PMCID: PMC4341112          DOI: 10.1097/GME.0000000000000314

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  27 in total

1.  A microcolorimetric determination of creatine in urine by the Jaffe reaction.

Authors:  H H TAUSSKY
Journal:  J Biol Chem       Date:  1954-06       Impact factor: 5.157

Review 2.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Authors:  Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

3.  Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition.

Authors:  Georgina E Hale; Claude L Hughes; Henry G Burger; David M Robertson; Ian S Fraser
Journal:  Menopause       Date:  2009 Jan-Feb       Impact factor: 2.953

4.  Age at natural menopause and mortality.

Authors:  G S Cooper; D P Sandler
Journal:  Ann Epidemiol       Date:  1998-05       Impact factor: 3.797

Review 5.  Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies.

Authors:  Leslee J Shaw; C Noel Bairey Merz; Carl J Pepine; Steven E Reis; Vera Bittner; Sheryl F Kelsey; Marian Olson; B Delia Johnson; Sunil Mankad; Barry L Sharaf; William J Rogers; Timothy R Wessel; Christopher B Arant; Gerald M Pohost; Amir Lerman; Arshed A Quyyumi; George Sopko
Journal:  J Am Coll Cardiol       Date:  2006-02-07       Impact factor: 24.094

6.  Diagnosis of polycystic ovary syndrome.

Authors:  Bradley Trivax; Ricardo Azziz
Journal:  Clin Obstet Gynecol       Date:  2007-03       Impact factor: 2.190

7.  Factors related to declining luteal function in women during the menopausal transition.

Authors:  N Santoro; S L Crawford; W L Lasley; J L Luborsky; K A Matthews; D McConnell; J F Randolph; E B Gold; G A Greendale; S G Korenman; L Powell; M F Sowers; G Weiss
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

8.  Lipid changes during the menopause transition in relation to age and weight: the Study of Women's Health Across the Nation.

Authors:  Carol A Derby; Sybil L Crawford; Richard C Pasternak; Maryfran Sowers; Barbara Sternfeld; Karen A Matthews
Journal:  Am J Epidemiol       Date:  2009-04-08       Impact factor: 4.897

9.  Relation of cardiovascular risk factors in women approaching menopause to menstrual cycle characteristics and reproductive hormones in the follicular and luteal phases.

Authors:  Karen A Matthews; Nanette Santoro; Bill Lasley; Yuefang Chang; Sybil Crawford; Richard C Pasternak; Kim Sutton-Tyrrell; Maryfran Sowers
Journal:  J Clin Endocrinol Metab       Date:  2006-02-21       Impact factor: 5.958

10.  Longitudinal changes in hypothalamic and ovarian function in perimenopausal women with anovulatory cycles: relationship with vasomotor symptoms.

Authors:  Joan H Skurnick; Gerson Weiss; Laura T Goldsmith; Nanette Santoro; Sybil Crawford
Journal:  Fertil Steril       Date:  2008-05-21       Impact factor: 7.329

View more
  1 in total

1.  Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Women's Health Across the Nation.

Authors:  Nanette Santoro; Sybil L Crawford; Samar R El Khoudary; Amanda A Allshouse; Sherri-Ann Burnett-Bowie; Joel Finkelstein; Carol Derby; Karen Matthews; Howard M Kravitz; Sioban D Harlow; Gail A Greendale; Ellen B Gold; Rasa Kazlauskaite; Dan McConnell; Genevieve Neal-Perry; Jelena Pavlovic; John Randolph; Gerson Weiss; Hsiang-Yu Chen; Bill Lasley
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.